Coverage of GeneVentiv’s approximately $2.5 million Direct to Phase II SBIR award from NHLBI supporting GENV-HEM development.
The announcement describes NIH funding for a large-animal study and assay development intended to support IND-enabling biodistribution and toxicology work for GENV-HEM.